Zealand Signs Helsinn to €140M Deal for GLP-2 Agonist in CID
Assistant Managing Editor
Danish biotech firm Zealand Pharma A/S partnered with Helsinn Healthcare in a potential €140 million (US$176.8 million) deal to develop its early clinical-stage glucagon-like peptide (GLP)-2 receptor agonist, ZP1846, in chemotherapy-induced diarrhea (CID).
Under the terms, Zealand granted Helsinn worldwide rights to the compound, except for the Nordic countries, where Zealand retains marketing rights.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter